Sugi Predict
/ Targets
/ BUB1B
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to BUB1B by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt |
PHASE4 | COMPLETED |
| A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression |
PHASE3 | RECRUITING |
| Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer |
PHASE2 | UNKNOWN |
| Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer |
PHASE2 | COMPLETED |
| Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) |
PHASE1/PHASE2 | NOT_YET_RECRUITING |
| Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma |
PHASE1/PHASE2 | COMPLETED |
| I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers |
PHASE1/PHASE2 | NOT_YET_RECRUITING |
| TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer |
PHASE2 | UNKNOWN |
| A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects |
PHASE1/PHASE2 | COMPLETED |
| Abemaciclib With or Without Atezolizumab for mCRPC |
PHASE2 | COMPLETED |
| TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC) |
PHASE1/PHASE2 | RECRUITING |
| Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors |
PHASE1/PHASE2 | COMPLETED |
| A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer |
PHASE1/PHASE2 | COMPLETED |
| Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma |
PHASE2 | COMPLETED |
| Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel |
PHASE1 | COMPLETED |
| AZD1775 for Advanced Solid Tumors |
PHASE1 | COMPLETED |
| Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors |
PHASE1 | COMPLETED |
| Study of ABT-751 in Patients With Refractory Hematologic Malignancies |
PHASE1 | COMPLETED |
| Phase I Study to Assess the Safety, Pharmacokinetics, & Pharmacodynamics of GSK923295 in Subjects w/ Refractory Cancer |
PHASE1 | COMPLETED |
| Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas |
PHASE1 | COMPLETED |
| Aurora B/C Kinase Inhibitor GSK1070916A in Treating Patients With Advanced Solid Tumors |
PHASE1 | COMPLETED |
| A Clinical Study of TQB3824 in Subjects With Advanced Cancer |
PHASE1 | UNKNOWN |
| PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck |
PHASE1 | COMPLETED |
| A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors |
PHASE1 | COMPLETED |
| Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia |
PHASE1 | WITHDRAWN |
| Tabectedin to Treat Children and Adolescents With Cancer |
PHASE1 | COMPLETED |
| Study of the Effect of Innate on the Inflammatory Response to Endotoxin |
nan | RECRUITING |
| Phosphoproteomic Patterns as a Novel Biomarker for Aurora and Polo-like Kinase Inhibitors in Non-Small Cell Lung Cancer |
nan | COMPLETED |
| Better Delineation of CDK13 Related Phenotype and Epigenetic Signature. |
nan | UNKNOWN |
| AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer. |
nan | RECRUITING |
Related proteins — ESM-2 sequence neighbours (a BUB1B binder may also engage these)